Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 16/20 | 0.35 |
| ▸ | CTSL | P07711 | 12/20 | 0.35 |
| ▸ | CTSS | P25774 | 12/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744818 | 0.89 | CTSK (0.46) | CTSK | |
| SCHEMBL6514175 | 0.79 | CTSK (0.51) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6488393 | 0.78 | CTSL (0.49) | CTSKCTSLCTSS | |
| SCHEMBL8265840 | 0.77 | CTSL (0.61) | CTSKCTSLCTSS | |
| SCHEMBL5743441 | 0.77 | CTSK (0.50) | CTSKCTSLCTSS | |
| SCHEMBL6475887 | 0.77 | CTSL (0.45) | CTSKCTSLCTSS | |
| SCHEMBL6514275 | 0.77 | CTSL (0.45) | CTSKCTSLCTSS | |
| SCHEMBL6481730 | 0.76 | CTSL (0.47) | CTSKCTSLCTSS | |
| SCHEMBL5744626 | 0.76 | CTSK (0.49) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6515438 | 0.76 | CTSK (0.49) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | CNR1 84/4885CNR2 190/4885CTSK 4/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | CNR1 50/4885CNR2 132/4885CTSK 5/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | CNR1 157/4885CNR2 596/4885CTSK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.